Download Nitric Oxide: Pulmonary Vasodilation

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts
Transcript
Editor: Dean F. Connors, MD, PhD
Author: Brent Richardson, MD
(2003-2004)
NITROC OXIDE:
PULMONARY VASODILATION
For the Boards…
PHARMACOLOGY
NITROC OXIDE: PULMONARY VASODILATION
Brent Richardson, MD (2003-2004)
1) Nitric Oxide (NO) is a pulmonary vasodilator administered as an inhaled gas. In the US it is
delivered in a 0.8% concentration with nitrogen (99.2%).
2) This compound leads to vasodilatation by binding to the heme moiety of cytosolic guanylate
cyclase, thus activating the enzyme. This leads to production of intracellular cyclic guanosine
3′, 5′-monophosphate, causing smooth muscle relaxation and vasodilatation.
3) NO, provides better oxygenation because it is administered only to areas of the lung that are
ventilated. In these areas it causes vasodilatation, thus improving V/Q matching.
4) It has systemic absorption but is quickly inactivated once entering the blood supply. It binds
with hemoglobin and forms methemoglobin and nitrate when the hemoglobin saturation is 60
– 100%. At lower saturations NO binds with deoxyhemoglobin to form nitrosylhemoglobin.
This breaks down to N2O and methemoglobin. Toxicity of NO arises from accumulation of
N2O and methemoglobin.
5) Dosage is usually 20ppm, however has been used from 5-80ppm. It may be administered for
up to 14 days, or until the underlying desaturation is resolved. Dosages of greater than 20ppm
lead to toxicity.
6) Uses for NO include:
a) Treatment of term and near term neonates with hypoxic respiratory failure associated
with clinical or echocardiographic evidence of pulmonary hypertension, when it
improves oxygenation and can reduce the need for ECHMO.
b) Treatment of acute increase in pulmonary vascular resistance (PVR) following
cardiopulmonary bypass.
c) Preoperative pulmonary hypertension with specific lesions including total anomalous
pulmonary venous return and congenital mitral stenosis
d) As a diagnostic tool to distinguish reactive pulmonary hypertension from fixed
anatomic obstructive disease in post surgical patients or those being worked up for
transplantation.
e) NO is intended for pediatric use, in adults its use is off label.
7) Contraindications to use of NO include any condition dependent on a right to left shunt.
Miller. Anesthesia, 5th ed Churchill Livingstone, Inc. Philadelphia: 2000, pp. 1834.
Mosby's Drug Consult. Mosby, Inc. 2003. St. Louis. Listing 003465.
Brent Richardson, MD
2003-2004